Review
Experimental infection of human volunteers

https://doi.org/10.1016/S1473-3099(18)30177-4Get rights and content

Summary

Controlled human infection (CHI) trials, in which healthy volunteers are experimentally infected, can accelerate the development of novel drugs and vaccines for infectious diseases of global importance. The use of CHI models is expanding from around 60 studies in the 1970s to more than 120 publications in this decade, primarily for influenza, rhinovirus, and malaria. CHI trials have provided landmark data for several registered drugs and vaccines, and have generated unprecedented scientific insights. Because of their invasive nature, CHI studies demand critical ethical review according to established frameworks. CHI-associated serious adverse events are rarely reported. Novel CHI models need standardised safety data from comparable CHI models to facilitate evidence-based risk assessments, as well as funds to produce challenge inoculum according to regulatory requirements. Advances such as the principle of controlled colonisation, the expansion of models to endemic areas, and the use of genetically attenuated strains will further broaden the scope of CHI trials.

Introduction

Controlled human infections (CHIs), through the transfer of body fluid such as serum,1 respiratory secretions,2 or faecal filtrates,3 laid the foundation for infectious disease research in the 17th century. Unparalleled human experimentation led to the identification of causative organisms (norovirus,3 influenza,2 dengue,4 and sarcocystis5), not only proving Koch's postulates, but also providing an opportunity to study incubation periods and clinical disease. Important discoveries were made such as the identification of toxins that caused diarrhoeal disease following instillation of Vibrio cholerae culture broth in volunteers in 1966.6 Although the ethics of these initial studies were often questionable, the realisation that they provided a core platform for the study of infections has resulted in the increased use of CHI models in the past decades. Ethical frameworks have been developed and rigorous independent review boards assess risks and benefits. CHI studies are moving from investigations that have exploratory and descriptive aims to trials that take a central position in the development pipeline of vaccines and drugs.7 CHI trials often act as a gatekeeper before proceeding to field efficacy trials, although in exceptional cases, can be accepted as proof of efficacy in phase 3 clinical development.8 Each CHI model has been designed with specific inocula, endpoints, or clinical procedures as a fit-for-purpose model (table). The development of novel CHI models and the exploitation of existing CHI models in the product development pipeline have been endorsed by large funders such as the Bill & Melinda Gates Foundation, the Wellcome Trust, and the UK Medical Research Council, who have dedicated funds to CHI models. CHI studies, by allowing preliminary efficacy testing in 10–100 participants, are cheaper than phase 2 and 3 clinical trials in endemic areas that often require sample sizes ranging from hundreds to 100 000 participants. Additionally, CHI studies allow for testing of many products, minimise the risk of late clinical failure, and reduce unnecessary exposure of potentially vulnerable populations to interventions (figure 1).

In CHI trials biomarkers, protective responses, and mechanisms of disease can be studied, which ultimately feed back into the product development pipeline to improve the next generation of medicines. Novel technological advances such as omics tools are used to identify risk factors including diet, microbiome, co-infections, or genetic background using complex multiparametric analyses. Pathogens are altered by genetic modification to identify key virulence genes (eg, NCT03067961) or to provide less virulent challenge inocula that can decrease the clinical severity of CHI models.36 In this Review, we provide an overview of the active CHI models, discuss their contribution to biomedical science, and suggest some predictions of what can be expected in this dynamic field in the future.

Section snippets

Ethical considerations

The son of Edward Jenner's gardener has become the historic symbol of CHI when he was inoculated with cowpox in 1796. Other infamous examples are infection of the MacDonalds' children with pertussis, infection of children with intellectual disability at Willowbrook State school in New York with hepatitis virus,37 and malaria infections in Nazi Germany.38 The Nuremberg Code (1946) and the Declaration of Helsinki (1964) now provide guidelines for the conduct of medical research involving human

CHI in product development

The contribution of CHI studies to the development of novel vaccines is shown by the Live Oral Cholera Vaccine CVD 103-HgR study in 197 healthy volunteers.8 CVD 103-HgR was licensed in several countries since 1993, but only recently in the USA.53 Volunteers were challenged by ingestion of wild-type V cholerae and were monitored for the occurrence of moderate or severe diarrhoea. The vaccine showed 90% efficacy, which, together with a good safety profile, led to licensure by the Food and Drug

Novel CHI models in poverty-related and neglected diseases

Because of the potential to reduce costs and time to registration, CHI models are particularly appealing for the development of products for resource-poor countries where infectious diseases are still responsible for considerable morbidity and mortality. Aside from malaria, Mycobacterium tuberculosis is an obvious infection that falls into this category. An M tuberculosis CHI model could provide a crucial platform for the selection of potential novel antibiotics and vaccine candidates. CHI

Colonisation models

Culture-independent technologies have revealed the diversity of the human microbiome.113 In an era of increasing antimicrobial resistance, the study of controlled colonisation in healthy volunteers has proven to be instrumental to dissect the dynamics of mucosal carriage of bacteria that precedes invasive bacterial infection. With regards to controlled colonisation, the upper respiratory tract microbiome has been the most studied.

The most frequently used model for colonisation is nasal

Scientific advances

CHI trials offer unprecedented opportunities to study host–pathogen interaction by taking multiple longitudinal samples before, during, and after infection. Profiling immune parameters and linking them to the clinical outcome is extremely valuable for identifying correlates of protection. The availability of validated correlates of protection will accelerate the development of novel vaccines by providing a surrogate endpoint for phase 2 field trials. Additionally, such insight could guide the

Future challenges and opportunities

The increasing costs for clinical development of novel drugs and vaccines for infectious diseases calls for tools to select candidates with highest probability of success. The concept of fast failure in which the development of unsuccessful candidates is stopped early is extremely important as it allows the reallocation of resources. CHI studies could be used as models for phase 2 clinical efficacy and so could reduce development risk, reduce overall costs, and increase risk-adjusted net

Search strategy and selection criteria

References were identified in PubMed using the search terms “experimental infection”, “human challenge”, “challenge study”, “challenge model”, “human infection”, “infection model”, “volunteer study”, “infection in volunteers”, “volunteer challenge”, and “controlled human infection” separately combined with each pathogen listed in the table. For each pathogen, the Mesh-term was combined with an [All Fields] search of common synonyms. We searched for articles published between Jan 1, 1900 and Oct

References (143)

  • J Zhu et al.

    Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma

    Chest

    (2014)
  • C Herzog

    Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR

    Travel Med Infect Dis

    (2016)
  • J Vekemans et al.

    Development of the RTS,S/AS malaria candidate vaccine

    Vaccine

    (2009)
  • T Ponnudurai et al.

    The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes

    Trans R Soc Trop Med Hyg

    (1982)
  • M Ciuca et al.

    Paludrine treatment of experimental malaria infection; effective minimum doses

    Trans R Soc Trop Med Hyg

    (1950)
  • M Sulyok et al.

    DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

    Lancet Infect Dis

    (2017)
  • JS McCarthy et al.

    Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

    Lancet Infect Dis

    (2017)
  • ML Clements et al.

    Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection

    Lancet

    (1984)
  • S Jones et al.

    DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

    Vaccine

    (2009)
  • FG Hayden et al.

    Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection

    Antiviral Res

    (1982)
  • MS Riddle et al.

    Status of vaccine research and development for norovirus

    Vaccine

    (2016)
  • DY Graham et al.

    Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers

    Gastroenterology

    (1983)
  • DG Evans et al.

    Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes

    FEMS Microbiol Immunol

    (1988)
  • AB Sabin

    Research on dengue during World War II

    Am J Trop Med Hyg

    (1952)
  • R Dolin et al.

    Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates

    J Infect Dis

    (1971)
  • X Chen et al.

    Observation on the clinical symptoms and sporocyst excretion in human volunteers experimentally infected with Sarcocystis hominis

    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi

    (1999)
  • C Benyajati

    Experimental cholera in humans

    BMJ

    (1966)
  • WH Chen et al.

    Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor

    Clin Infect Dis

    (2016)
  • AC Teirlinck et al.

    NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections

    J Infect Dis

    (2013)
  • M Roestenberg et al.

    Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites

    Am J Trop Med Hyg

    (2013)
  • DA Shirley et al.

    The utility of human challenge studies in vaccine development: lessons learned from cholera

    Vaccine (Auckl)

    (2011)
  • CS Waddington et al.

    An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution

    Clin Infect Dis

    (2014)
  • CK Porter et al.

    The shigella human challenge model

    Epidemiol Infect

    (2013)
  • RL Atmar et al.

    Norovirus vaccine against experimental human Norwalk virus illness

    N Engl J Med

    (2011)
  • R Frenck et al.

    Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans

    J Infect Dis

    (2012)
  • JF Gritzfeld et al.

    Experimental human pneumococcal carriage

    J Vis Exp

    (2013)
  • SM Spinola et al.

    Immunopathogenesis of Haemophilus ducreyi infection (chancroid)

    Infect Immun

    (2002)
  • SA CF Cross et al.

    From rabbits to humans: the contributions of Dr Theodore E Woodward to tularemia research

    Clin Infect Dis

    (2007)
  • AM Deasy et al.

    Nasal inoculation of the commensal Neisseria lactamica inhibits carriage of Neisseria meningitidis by young adults: a controlled human infection study

    Clin Infect Dis

    (2015)
  • DR Tribble et al.

    Campylobacter jejuni strain CG8421: a refined model for the study of campylobacteriosis and evaluation of campylobacter vaccines in human subjects

    Clin Infect Dis

    (2009)
  • CL Chappell et al.

    Cryptosporidium hominis: experimental challenge of healthy adults

    Am J Trop Med Hyg

    (2006)
  • HL DuPont et al.

    The infectivity of Cryptosporidium parvum in healthy volunteers

    N Engl J Med

    (1995)
  • J Feary et al.

    Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study

    Clin Exp Allergy

    (2009)
  • RO Darouiche et al.

    Bacterial interference for prevention of urinary tract infection

    Clin Infect Dis

    (2012)
  • AM Minassian et al.

    A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin

    J Infect Dis

    (2012)
  • MM Hobbs et al.

    Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC

    Front Microbiol

    (2011)
  • TE Nash et al.

    Antigenic variation of Giardia lamblia in experimental human infections

    J Immunol

    (1990)
  • DY Graham et al.

    Challenge model for Helicobacter pylori infection in human volunteers

    Gut

    (2004)
  • HC Dobinson et al.

    Evaluation of the clinical and microbiological response to Salmonella paratyphi A infection in the first paratyphoid human challenge model

    Clin Infect Dis

    (2017)
  • MJ Anderson et al.

    Experimental parvoviral infection in humans

    J Infect Dis

    (1985)
  • Cited by (102)

    • Viral infection and allergy status impact severity of asthma symptoms in children with asthma exacerbations

      2022, Annals of Allergy, Asthma and Immunology
      Citation Excerpt :

      Other viruses have also been implicated in exacerbations of asthma, including respiratory syncytial virus (RSV), coronaviruses, human metapneumovirus, human parainfluenza viruses, and enteroviruses.4-6 In an effort to understand mechanisms of virus-related asthma exacerbations (VRAEs), subjects with controlled asthma have undergone experimental inoculation with RV.7-10 Although this approach has provided information regarding immune responses and symptoms during VRAE, it has become clear that more research is needed in those with uncontrolled asthma, as clinical outcomes are often worse within this population.

    • Remodelling selection to optimise disease forecasts and policies

      2024, Journal of Physics A: Mathematical and Theoretical
    View all citing articles on Scopus
    View full text